Avis et décisions de la HAS
La recommandation relative à la prise en charge à titre dérogatoire de l’infliximab (REMICADE) dans le cadre d’une recommandation temporaire d’utilisation, ci-jointe, est adoptée.
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
vsEqykVr5kgJhp5a